Article citationsMore>>

J. Svoboda, C. Andreadis, L. H. Downs, W. T. Miller Jr., D. E. Tsai and S. J. Schuster, “Regression of Advanced Non-Splenic Marginal Zone Lymphoma after Treatment of Hepatitis C Virus Infection,” Leuk Lymphoma, Vol. 46, No. 9, 2005, pp. 1365-1368.
http://dx.doi.org/10.1080/104281905001028289

has been cited by the following article:

• TITLE: Splenic Marginal Zone Lymphoma in a Patient with Positive Hepatitis B Virus Serology*

  AUTHORS: Qureshi Iman, Eden Dewi, Bokhari Syed

  KEYWORDS: Splenic Marginal Zone Lymphoma; Hepatitis B

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.4, December 13, 2013

  ABSTRACT: We present a case in which an elderly woman diagnosed with a splenic marginal zone lymphoma (MZL) was found to have positive Hepatitis B serology. Link with Hepatitis C virus is well documented but reports of association of Hepatitis B virus (HBV) with splenic marginal zone lymphoma are still emerging. A 69-year-old lady presented with weight loss, pancytopenia and marked splenomegaly. Prior to commencing treatment, Hepatitis B serology confirmed Hepatitis B infection. She was treated with Chlorambucil along with anti-hepatitis B prophylaxis and HBV PCR monitoring. She had an excellent response to treatment with resolution of symptoms and splenomegaly. This case highlights the importance of testing for hepatitis B serology in patients diagnosed with splenic MZLs as causative agent. Although the association between HCV is well documented in the literature, a relationship between HBV may also be important. Also, chemotherapy +/- Rituximab for splenic MZL is associated with the reactivation of latent infections; hence providing prophylactic cover for pre-existing latent HBV infection may be required to prevent reactivation as in this case.